Weight
loss with Detemir Insulin Gives Added Therapeutic Value to Treatment
The
weight gain experienced by thousands of people with diabetes who rely
upon multiple injections of insulin may soon be a thing of the past
In
three clinical trials reported at the EASD conference in September–
conducted with a total of more than 1,300 people with diabetes – the
weight loss achieved with once-daily administration of insulin Detemir
represented a significant therapeutic benefit, according to the lead
author of one of the studies, Dr Eberhard Standl.
Insulin
Detemir is a soluble basal insulin analogue with neutral pH and a
unique mechanism of protraction providing a smooth and predictable
action profile.
Dr
Standl, from Munich Diabetes Research Institute, Germany, commented:
“The fact that insulin Detemir is associated with such favorable
effects on body weight represents a significant clinical benefit, in
addition to the many other advantages this new agent offers over other
forms of insulin.”
The
showed a very favorable outcome on weight with a significant weight
loss for insulin Detemir(2). These findings were supported by a third
study in which the authors observed a decrease in body weight for the
insulin Detemir group and an increase for the standard Neutral
Protamine Hagedorn (NPH) insulin group after 6 months treatment(3).
All
three studies show that at the same level of glycemic control as
measured by HbA1C, insulin Detemir provides a significant reduction in
body weight and reduced risk of nocturnal hypoglycemia. Highlights of
these studies are summarized in this
PDF chart Insulin Detemir is now undergoing further Phase 3
clinical trials in people with both Type 1 and Type 2 diabetes and
actively regulate how our bodies process and use fats. Future drug
discovery may depend on the role of fat itself."
Nature
Med 2002 University
Of Pennsylvania Medical Center
================================
Special
News Bulletin
Sankyo
Pharma Announce Availability of the GlucoWatch® G2™ Biographer
See
item #15
See
item 15
